colorectal cancer large bowel cancer
Conditions
Interventions
Two questionnaires with approximately 15 multiple-choice questions shall be
given during
this study: the first before randomization and the second after completion of
the CT-colonography procedure
Janssen-Cilag, Tilburg, The Netherlands) 7.5 mcg/kg intravenously through the
cannula. The participants from group 2 will receive a placebo, in this study a
0.9% saline solution. This placebo is cho
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 18 tot 85 years Written informed consent Scheduled for CT-colonography for symptoms or increased risk for colorectal cancer (including patients referred after incomplete colonoscopy)
Exclusion criteria
Exclusion criteria: Hypotension (systolic blood pressure 4) Use of MAO-inhibitors or within two weeks before the CT-colonography procedure Use of barbiturates, opiates or daily benzodiazepine use Known increased intracranial pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference between the alfentanil group and placebo group in maximum pain score during insufflation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences in: *Pain score in all insufflation positions (left and right decubitus, supine and prone) and the average pain score *Pain and burden of all CT-colonography aspects (telebrix, cannula insertion, insufflation) and total pain and burden of CT-colonography *Side-effects of alfentanil during CT-colonography including: - respiratory effects (apnoea, respiratory frequency and blood oxygenation) - hemodynamics (heart rate and blood pressure) *Procedure and recovery time *The most painful and most burdenful aspect of CT-colonography | — |
Countries
Netherlands
Outcome results
None listed